Search Results
Jun 16, 2026, 08:00 ET SASE 1Q 2026 Revenue Climbs 21 Percent to Over $3 B Driven by AI Governance, According to Dell'Oro Group
security, networks, and data center industries, the Secure Access Service Edge (SASE) market grew 21 percent year-over-year (Y/Y) in 1Q 2026 to over $3 B. The quarter reinforced that SASE is a strategic platform investment, with enterprises funding cloud-delivered security, branch modernization, and AI-era
More news about: Dell'Oro Group
Jun 16, 2026, 08:00 ET ProJenX Announces a Development Update for Prosetin, a First-in-Class, CNS-Penetrant MAP4K Inhibitor
PRO-101, the Phase 1b study of prosetin in ALS participants, is fully enrolledProsetin is safe and well-tolerated over long-term dosing at target active exposures in ALS participants, and demonstrates exposure-related, statistically significant target engagementData
More news about: ProJenX
Jun 16, 2026, 08:00 ET Mars Accelerates Sustainability Progress with All U.S. Operations now Powered by 100% Renewable Electricity
support the decarbonization of its value chain while strengthening long-term resilience. This included plans to invest an estimated $2B in U.S.-based manufacturing and €1B in its European Union operations by the end of 2026. In addition, Mars launched the Mars Sustainability Investment Fund, with a total
More news about: Mars, Incorporated
Jun 16, 2026, 08:00 ET Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). The Company's preclinical pipeline includes development of an oral product candidate
More news about: Acurx Pharmaceuticals, Inc.
Jun 16, 2026, 08:00 ET Verge Labs Unveils vBx: A Breakthrough Foundation Model for Precision Neurology
signals in the brain that indicate why a given patient is likely to respond as they do.Verge also benchmarked vBx-1.0 on data from its own Phase 1b trial of VRG50635, a PIKfyve inhibitor, in which approximately one third of ALS patients discontinued after their first dose, for unknown reasons. When
More news about: Verge Labs
Jun 16, 2026, 08:00 ET Contango Silver & Gold Intersects 972.10 g/t Gold at Lucky Shot and Continues Underground Exploration Development Program
Figures 4A and 4B show the earlier interpretation of the Lucky Shot vein model, which was constrained by a more limited drilling dataset and relied on broader correlation of vein intercepts across areas with less underground drill density. The narrow black lines shown in Figures 4A and 4B represent the
More news about: Contango Silver & Gold Inc.
Jun 16, 2026, 08:00 ET 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
framework for all subsequently FDA-approved CAR-T therapies. In addition, Dr. Sadelain identified a molecule named CD19 as a potential target for treating B cell malignancies, which include leukemias and lymphomas, and provided the first demonstration that human CD19 CAR T cells could treat cancer in mice.
More news about: The Tang Prize Foundation
Jun 16, 2026, 07:58 ET Cat Lake First Nation and First Mining Gold Reach Milestone Agreement on Mobilizing the Cat Lake All-Season Access Road
law. Cautionary Note to United States Investors The Company is a "foreign private issuer" as defined in Rule 3b-4 under the United States Securities Exchange Act of 1934, as amended, and is eligible to rely upon the Canada-U.S. Multi-Jurisdictional Disclosure System,
More news about: First Mining Gold Corp.
Jun 16, 2026, 07:30 ET SpliSense Secures Up to $13 Million from the Cystic Fibrosis Foundation to Advance Phase 2b Study of SPL84 for Cystic Fibrosis
first-ever clinical proof-of-concept for an inhaled antisense oligonucleotide therapy in a lung diseaseFunding supports the ongoing global Phase 2b study evaluating SPL84 in people with cystic fibrosis carrying the 3849+10kb C→T mutation who are receiving standard-of-care CFTR modulators; topline
More news about: SpliSense
Jun 16, 2026, 07:30 ET First Mining Announces Springpole Project Authorization from Cat Lake First Nation and Lac Seul First Nation Following the Completion of the Anishnaabe Led Impact Assessment
required by law. Cautionary Note to United States Investors The Company is a "foreign private issuer" as defined in Rule 3b-4 under the United States Securities Exchange Act of 1934, as amended, and is eligible to rely upon the Canada-U.S. Multi-Jurisdictional Disclosure System,
More news about: First Mining Gold Corp.
Jun 16, 2026, 07:00 ET commercetools Partners with Mirion Technologies on B2B Commerce AI Agent to Reduce Manual Order Processing and Accelerate Revenue
commercetools and Mirion Technologies form a co-design partnership to develop the next generation of AI-powered B2B commerce agents.The B2B Intake Agent converts emails, PDFs, spreadsheets, and other unstructured requests into quotes and carts in minutes.Agent helps
More news about: commercetools
Jun 16, 2026, 07:00 ET Cizzle Bio Announces Laboratory Validation of CIZ1B Biomarker Blood Test for Early Lung Cancer at OmniHealth Diagnostics
"The laboratory validation of CIZ1B marks an important milestone." --Bill Behnke, CEO of Cizzle Bio, Inc.The CIZ1B biomarker test is a novel, ELISA-based immunoassay that detects a protein variant associated with early-stage
More news about: Cizzle Bio
Jun 16, 2026, 07:00 ET Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
inform a Phase 3 trial. In oHCM, dosing was guided by left ventricular outflow tract gradient (LVOT-G), while in nHCM, dosing was guided by N-terminal pro-B-type natriuretic peptide (NT-proBNP), a key biomarker of heart failure. Patients in both groups received doses ranging from 25 mg to 150 mg. A total of
More news about: Edgewise Therapeutics
Jun 16, 2026, 06:59 ET Core Materials Market worth $4.47 billion by 2031 - Exclusive Report by MarketsandMarkets™
alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.Today, 80%
More news about: MarketsandMarkets
Jun 16, 2026, 06:52 ET 자동차와 축구가 만들어내는 완벽한 시너지… GAC의 파워를 경험하라
multimedia:https://www.prnewswire.com/kr/news-releases/uC790uB3D9uCC28uC640u002DuCD95uAD6CuAC00u002DuB9CCuB4E4uC5B4uB0B4uB294u002DuC644uBCBDuD55Cu002DuC2DCuB108uC9C0u2026u002Du0067u0061u0063uC758-302801541.htmlSOURCE
More news about: GAC
Jun 16, 2026, 06:45 ET TELUS Digital to Showcase AI-Powered Customer Experience Solutions at Customer Contact Week Las Vegas 2026
Partnerships, reveals a striking gap: while revenue growth ranks second among the results enterprises already report from CX partnerships, outbound B2B and B2C sales remain among the least outsourced functions. This points to a significant untapped opportunity for enterprises willing to rethink how they
More news about: TELUS Digital
Jun 16, 2026, 06:45 ET TELUS Digital to Showcase AI-Powered Customer Experience Solutions at Customer Contact Week Las Vegas 2026
Partnerships, reveals a striking gap: while revenue growth ranks second among the results enterprises already report from CX partnerships, outbound B2B and B2C sales remain among the least outsourced functions. This points to a significant untapped opportunity for enterprises willing to rethink how they
More news about: TELUS Digital
Jun 16, 2026, 06:30 ET Sensor Tower State of AI 2026 Report: Global Time Spent on Generative AI Apps Projected to More Than Double Year-Over-Year
reached $1.3B (Jan–May 2026), up 48% YoY.AI Features Are Table Stakes: 200,000+ apps now mention AI in their descriptions; these apps are on track for ~10B downloads in H1 2026 (+25% YoY).Web Engagement Scales: Gen AI websites generated 67B+ visits and ~23B hours in Q1
More news about: Sensor Tower
Jun 16, 2026, 06:30 ET Sensor Tower State of AI 2026 Report: Global Time Spent on Generative AI Apps Projected to More Than Double Year-Over-Year
reached $1.3B (Jan–May 2026), up 48% YoY.AI Features Are Table Stakes: 200,000+ apps now mention AI in their descriptions; these apps are on track for ~10B downloads in H1 2026 (+25% YoY).Web Engagement Scales: Gen AI websites generated 67B+ visits and ~23B hours in Q1
More news about: Sensor Tower
Jun 16, 2026, 06:30 ET Hyperscale Data Bitcoin Treasury and Cash of Approximately $87.1 Million Represents Approximately 73.34% of Current Market Capitalization of Common Stock
as-converted basis. The Divestiture will occur through the voluntary exchange of the Series F Preferred Stock for shares of Class A Common Stock and Class B Common Stock of ACG (collectively, the "ACG Shares"). The Company reminds its stockholders that only those holders of the Series F Preferred Stock
More news about: Hyperscale Data Inc.
Jun 16, 2026, 06:20 ET PSP Investments outperforms 10-year benchmarks and posts solid performance in fiscal 2026
Public Market Equities$92.8B20.6 %
More news about: PSP Investments
Jun 16, 2026, 06:07 ET RBLX Court Deadline: Roblox Corporation Investors are Notified of the Important August 7 Deadline in the Pending Securities Fraud Class Action Lawsuit
have until August 7, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Roblox common stock. The class action is pending in the U.S. District Court
More news about: Bleichmar Fonti & Auld LLP
Jun 16, 2026, 06:07 ET GRAL Court Deadline: GRAIL, Inc. Investors are Notified of the Important August 4 Deadline in the Pending Securities Fraud Class Action Lawsuit
have until August 4, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in GRAIL common stock. The class action is pending in the U.S. District Court
More news about: Bleichmar Fonti & Auld LLP
Jun 16, 2026, 06:07 ET ADMA Court Deadline: ADMA Biologics Investors are Notified of the Important August 10 Deadline in the Pending Securities Fraud Class Action Lawsuit
until August 10, 2026, to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in ADMA securities. The class action is pending in the U.S. District Court for
More news about: Bleichmar Fonti & Auld LLP
Jun 16, 2026, 06:00 ET PSP Investments outperforms 10-year benchmarks and posts solid performance in fiscal 2026
Public Market Equities$92.8B20.6 %
More news about: PSP Investments